Search

Your search keyword '"Kersten, Marie José"' showing total 837 results

Search Constraints

Start Over You searched for: Author "Kersten, Marie José" Remove constraint Author: "Kersten, Marie José" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
837 results on '"Kersten, Marie José"'

Search Results

2. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

5. A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

6. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry

10. Moderators of exercise effects on self-reported cognitive functioning in cancer survivors: an individual participant data meta-analysis

11. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

12. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

13. Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials

14. Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled Trial.

15. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

16. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial

18. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

26. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

27. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

28. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

30. Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

31. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

32. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

33. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

34. Impact of etoposide and ASCT on survival among patients aged

35. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

37. Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands

38. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

39. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

40. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

41. Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities

42. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy

48. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

49. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study

Catalog

Books, media, physical & digital resources